Table 1 Patients and Controls baseline characteristics.
Patients | Controls | p-value | |
|---|---|---|---|
N = 35 | N = 35 | χ2 test or Fisher exact test | |
Average (standard deviation), or Number (%) | Average (standard deviation), or Number (%) | ||
Age (years) | 51,1 (±9,3) | 51,00 (±9,47) | 0,96 |
Sex (M) | 6 (17,1%) | 6 (17,1%) | 1,00 |
BMI | 24,4 (±3,6) | 24,2 (±4,1) | 0,73 |
Smoke | 11(31,4%) | 8 (24,3%) | 0,72 |
Alcohol abuse (≥2 unit/d) | 0 (0,0%) | 0 (0,0%) | — |
Alcohol consumption (≤1unit/d) | 15 (50,0%) | 10 (30,3%) | 0,14 |
Total Cholesterolemia (mg/dl) | 214,7(±30,0) | 198,6 (33,2%) | 0,10 |
Creatinine (mg/dl) | 0,79 (±0,11) | 0,85 (±0,14) | 0,09 |
Hypertension | 7 (20.0%) | 4 (11.4%) | 0,29 |
Homocysteine (micromole/l) | 11.45 (±3.08) | 12.09 (±3.91) | 0,86 |
Migraine | 20 (57.1%) | 13 (37.1%) | 0,21 |
Drugs | |||
1. Antiplatelet agents | 5 (14,3%) | 0 (0%) | |
2. Statins | 4 (11,4%) | 1 (2,9%) | |
3. Antihypertensive | 6 (17,1%) | 2 (5,7%) | |
4. Folate and B12 vitamins | 2 (5,7%) | 1 (2,9%) | |
Time from MRI to visit (months) | 10,2 (±9,5) | 8,6 (±9,6) | 0,57 |
Fazekas score | |||
5. Total | 2,69 (±1,12) | 0 | — |
6. Periventricular | 1,12 (±0,67) | 0 | — |
8. Deep white matter | 1,64 (±0,70) | 0 | — |
